Site-targeted C3 inhibition reduced neurodegeneration in an ALS mouse model
Original source
Site-targeted proximal complement C3 inhibition, but not C5 blockade, attenuates neurodegeneration in a mouse model of amyotrophic lateral sclerosis: Implications for failed clinical trials. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Mouse
Population inferred from the title and abstract by Compass.
A site-targeted complement C3 inhibitor improved survival and motor outcomes in hSOD1G93A mice when treatment began at symptom onset. A C5 inhibitor did not produce the same benefits, despite suppressing its intended target. The findings suggest that local C3-related activity may be more important than C5a or membrane attack complex activity in this mouse model.
Why this matters
The study supports further investigation of site-targeted C3 inhibition as a potential ALS treatment strategy. However, this was an animal study, so it does not change treatment for people with ALS and does not establish that the approach will work in humans.
Limitations and context
The results came from hSOD1G93A mice treated from symptom onset, not from people with ALS. The study compared two experimental inhibitors and did not demonstrate clinical benefit or safety in humans. Human trials would be needed to determine whether site-targeted C3 inhibition is effective in ALS.